ERIN HARTSBURG: Open Payments
NPI 1356944185 · OKLAHOMA CITY, OK. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$543 in 27 payments from 10 companies in 2025. Trend: 2023 $1,909 · 2024 $180 · 2025 $543
Food & beverage: $543
| Company | Payments | Amount |
|---|---|---|
| Exelixis Inc. | 5 | $100 |
| Novartis Pharmaceuticals Corporation | 4 | $89 |
| Bayer Healthcare Pharmaceuticals Inc. | 4 | $68 |
| AstraZeneca Pharmaceuticals LP | 3 | $63 |
| Merck Sharp & Dohme LLC | 2 | $59 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $57 |
| Incyte Corporation | 2 | $47 |
| ARRAY BIOPHARMA INC | 2 | $33 |
| Deciphera Pharmaceuticals Inc. | 1 | $17 |
| THD America, Inc. | 1 | $11 |
Products named: CABOMETYX, LUTATHERA, Stivarga, KEYTRUDA, FRUZAQLA, BRAFTOVI, ZYNYZ, JAKAFI.
Industry payments across OK — which companies pay providers there.
